Date updated:04-28-2007
Bio

-
POZN
Pozen - $5.61
- -1.92%
- $5.76
Blockbuster (anticipated yearly sales of more than 1 Billion) Drug Candidates: 1. Trexima for migraines...August FDA decision. The analysts are expecting approval. Glaxo-Smith-Klein is the developmental/commercialization partner. PN 400 Arthritis medicine...Phase 3 trials to start this year. Astra Zeneca (375 million contract) is the developmental/commercialization partner. PA 325 Safer (in terms of gastrointestinal damage) Aspirin. Stellar results from the first study were released on March 6th.

-
DNDN
Dendreon Corporat - $28.61
- +2.99%
- $28.18
40% short , it may not cure cancer ,but it surely can give a bit more time on earth and with a better qaulity of life. I have seen the effect of rediation, my fathrer died from it , and now my best friend is undergoing the same.

-
ISPH
Inspire Pharmaceu - $5.48
- +3.40%
- $5.29
AzaSite been approved . Inspire expects to launch AzaSite in the latter end of the third quarter, and projects the product will generate $30 million to $45 million in 2008 sales . Much more potential !

-
VION
Vion - $0.00
- N/A
- $N/A
Recent accumulation by institution and insiders Vion has two agents in clinical trials. Cloretazine® (VNP40101M), a unique alkylating agent, is being evaluated in: (i) a Phase III trial in combination with cytarabine in relapsed acute myelogenous leukemia and (ii) a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. An additional trial of Cloretazine® (VNP40101M) as a single agent in small cell lung cancer is also underway. Triapine®, a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. In preclinical studies

-
ONXX
Onyx Pharmaceutic - $26.60
- +0.11%
- $26.67
possible buy out? The company is developing Nexavar(R), a small molecule drug, with Bayer Pharmaceuticals

-
ONXX
Onyx Pharmaceutic - $26.60
- +0.11%
- $26.67
possible buy out? The company is developing Nexavar(R), a small molecule drug, with Bayer Pharmaceuticals

-
ACEL
Acel - $0.00
- N/A
- $N/A
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates in clinical development. Vanda's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia and bipolar disorder and has recently completed its Phase III program in schizophrenia. Vanda's second product candidate, VEC-162, is a compound for the treatment of sleep and mood disorders which is currently in Phase III for insomnia. Vanda's third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness that is in a Phase II clinical trial.

-
IDMI
Idmi - $0.00
- N/A
- $N/A
Biopharmaceutical company IDM Pharma Inc. said Tuesday it will meet with a Food and Drug Administration advisory panel May 9 to discuss its application for Junovan. The drug -- its lead candidate -- is aimed at treating osteosarcoma, a type of malignant bone cancer, following surgical resection in combination with chemotherapy. IDM will meet with the Oncologic Drugs Advisory Committee, which will then give its recommendation to the FDA.
- Top Professional Portfolios
- 1. Navellier & Associ...
- 2. Fidelity Contrafund - ...
- 3. Argus Management
- 4. WisdomTree Intl Consum...
- 5. Charlie Munger
- show all
- Top Do-It-Yourself Portfolios
- » John Shier
- » Joy
- » tsamanuli Portfolio 1
- » brueckenc Portfolio 1
- » Fundsonly Portfolio 1
- show all
- Most Viewed Portfolios
- » Warren Buffett
- » George Soros
- » T. Boone Pickens - BP Cap...
- » Carl Icahn
- » Renaissance Technologies
- show all
By Roberto Pedone Posted on Nov. 6, 2009 According to Jim Cramer, the bears are tellinginvestors six lies. On Wednesday’s “Mad Money” TV show, Cramer said if you ...
By Roberto Pedone Posted on Nov. 5, 2009 The traders on CNBC’s “Fast Money” told their viewers what they must know after Warren Buffett announced on Tuesday his l...
By Jonas Elmerraji Posted on Nov. 4, 2009 For investors who seek out short-squeeze opportunities, there’s no time as important as earnings season. Earnings are one of...
By Stockpickr Staff Posted on Nov. 4, 2009 Regardless of why a stock is in the news, it never hurts to hear what a professional investor has to say about it. The key is...
A. Also dont like that it has relations
with the god aweful never profitable
automobile industry, but is moving its
resources to the building side and
conserving energy for them.
A. The only one I own : SLX,
too hard pick a winner out all of them
Analyst Downgrades for Nov. 2, 2009. Read more here. more
Here are some of the largest % gainers from Nov. 2, 2009. more
Here is a list of some of the biggest stocks that hit 52-week lows on Nov. 2, 2009. more











Comments not available